GO
Loading...

Pharmaceuticals

More

  • Paying for diabetes pandemic     Thursday, 17 Jul 2014 | 8:49 AM ET

    Lars Sorensen, Novo Nordisk CEO, explains why the Affordable Care Act isn't affordable for people with diabetes.

  • UPDATE 1-Medical products boost Baxter's sales Thursday, 17 Jul 2014 | 8:33 AM ET

    July 17- Medical device and drug maker Baxter International Inc reported higher-than-expected quarterly earnings and revenue, helped by surging sales in its medical products division. Net adjusted income rose to $692 million, or $1.26 per share in the second quarter ended June 30, from $639 million, or $1.16 per share, a year earlier.

  • ZURICH, July 17- Swiss drugmaker Novartis posted a quarterly rise in sales that missed expectations and said it would focus on eking out gradual cost savings to boost margins as it prepares a radical business overhaul.

  • Novartis cites momentum in 3 percent profit rise Thursday, 17 Jul 2014 | 2:07 AM ET

    GENEVA— Swiss pharmaceutical company Novartis AG posted a 3 percent rise in second-quarter profits Thursday, reflecting what it described as solid growth and an increased focus on core products.

  • The billionaire investors, who have been at odds over nutrition and diet company Herbalife, made up in public on Wednesday, ending a decade long feud that exploded on cable television 18 months ago.

  • Studies see new risks for cholesterol drug niacin Wednesday, 16 Jul 2014 | 5:10 PM ET

    New details from two studies reveal more side effects from niacin, a drug that hundreds of thousands of Americans take for cholesterol problems and general heart health. Some prominent doctors say the drug now seems too risky for routine use. Those details are in this week's New England Journal of Medicine.

  • NEW YORK, July 16- Billionaire investor John Paulson on Wednesday called Valeant Pharmaceuticals International Inc a "very serious acquirer" and predicted that Allergan Inc cannot rebuff the drug maker on its own.

  • *Three ex-GSK staff seek labour arbitration in Shanghai. BEIJING/ SHANGHAI, July 16- Three former Chinese employees of GlaxoSmithKline PLC, which is embroiled in a long-running corruption probe in China, are seeking compensation for illegal dismissal from their jobs, a lawyer representing them told Reuters.

  • Abbott 2Q profit falls on higher taxes, revenue up Wednesday, 16 Jul 2014 | 9:22 AM ET

    The generic drugmaker Mylan Inc. announced this week that it is buying Abbott's generic-drugs business in developed markets for stock valued at about $5.3 billion. For the period ended June 30, Abbott— which makes infant formula like Similac as well as medical devices and drugs— earned $466 million, or 30 cents per share.

  • *Sanofi mulls fate of 200 older drugs including Plavix. *Sanofi also held talks with TPG and Warburg Pincus. PARIS, July 16- Sanofi has held talks with Abbott Laboratories, Mylan and private equity firms over the possible sale of a 6.3 billion euro portfolio of mature drugs, according to an internal document seen by Reuters.

  • Sanofi mulls selling mature drug portfolio: Report Wednesday, 16 Jul 2014 | 8:39 AM ET

    Sanofi talked with Abbott Laboratories, Mylan and private equity firms over selling a portfolio of mature drugs, according to a document.

  • *Three ex-GSK staff seek labour arbitration in Shanghai. BEIJING/ SHANGHAI, July 16- Three former Chinese employees of GlaxoSmithKline PLC, which is embroiled in a long-running corruption probe in China, are seeking compensation for illegal dismissal from their jobs, a lawyer representing them told Reuters.

  • Next global epidemic?     Tuesday, 15 Jul 2014 | 1:40 PM ET

    CNBC's Meg Tirrell reports which biotech companies are working on what analysts say could be the next big biotech catalyst known as NASH, or nonalcoholic steatohepatitis.

  • Deadly Ebola virus spreads—and so do fears Tuesday, 15 Jul 2014 | 11:12 AM ET
    Government health workers administer blood tests to check for the Ebola virus in Kenema, Sierra Leone, June 25, 2014.

    Hundreds have died in West Africa from the Ebola virus. With no known cure and a high mortality rate, alarm is real.

  • ZURICH, July 15- Swiss drugmaker Novartis has struck an agreement with Google to develop "smart" contact lenses that would help diabetics track their blood glucose levels or restore the eye's ability to focus. The device for diabetics would measure glucose in tear fluid and send the data wirelessly to a mobile device, Novartis said.

  • July 14- Generic drugmaker Mylan Inc said on Monday it would buy Abbott Laboratories' branded specialty and generics business in developed markets outside the United States in a $5.3 billion deal that will bolster its product line and also cut its tax bill.

  • FACTBOX-M&A frenzy transforming global pharma Monday, 14 Jul 2014 | 9:27 AM ET

    July 14- Several multi-billion dollar deals and bids have made 2014 a busy year for healthcare acquisitions, despite Pfizer pulling its $118 billion offer for AstraZeneca.

  • Mylan in $5.3B deal for Abbott's generics assets Monday, 14 Jul 2014 | 8:47 AM ET

    Mylan said it would buy Abbott Labs' generics business outside the United States in an all-stock transaction valued at about $5.3 billion.

  • *Move aimed towards making drugs more affordable in India. MUMBAI, July 14- India has capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV, a move likely to hit the profit margins of drug firms such as Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd..

  • US STOCKS-Futures higher on M&A after down week Monday, 14 Jul 2014 | 7:40 AM ET

    *Shire accepts Abbvie takeover offer. *London- listed drugmaker Shire Plc succumbed to an increased 31 billion pounds takeover offer from Abbvie Inc, ending a long-running courtship largely motivated by tax rates. U.S.-listed shares of Shire rose 2.4 percent to $255.10 while Abbvie shed 0.7 percent to $54.56 in premarket trade.